MedTrace Logo

TREAT-BE Study (Treatment With Resection and Endoscopic Ablation Techniques for Barrett's Esophagus)

NCT02634645 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 5000

Last updated 2025-02-28

No results posted yet for this study

Summary

A prospective outcomes study in patients with and esophageal cancer (EAC) and Barrett's esophagus (BE) associated neoplasia being evaluated for endoscopic eradication therapy (EET).

Conditions

  • Barrett's Esophagus
  • Esophageal Cancer

Interventions

PROCEDURE

Endoscopic eradication therapies (EET)

Endoscopic eradication therapies (EET) includes endoscopic mucosal resection (EMR), which describes the process by which the area most likely to harbor highest grade of dysplasia/neoplasia is removed; radiofrequency ablation (RFA), which describes the process by which Barrett's segments are removed via burning/ablation; and cryotherapy.

PROCEDURE

Esophagectomy

The esophagus is surgically removed

DRUG

Chemotherapy

Chemical substances are used to treat cancer

RADIATION

Radiation

Cancer cells are destroyed by radiation therapy.

Sponsors & Collaborators

  • Northwestern University Feinberg School of Medicine

    collaborator OTHER

  • University of California, Los Angeles

    collaborator OTHER

  • H. Lee Moffitt Cancer Center and Research Institute

    collaborator OTHER

  • California Pacific Medical Center

    collaborator OTHER

  • University of Colorado, Denver

    lead OTHER

Principal Investigators

  • Sachin Wani, MD · University of Colorado, Denver

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-01-31
Primary Completion
2027-01-31
Completion
2027-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02634645 on ClinicalTrials.gov